MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: 12 February 2014
TO: NDA 206162
FROM: Erika Pfeiler, Ph.D.
Microbiologist
CDER/OPS/NDMS
THROUGH: John Metcalfe, Ph.D.
Senior Review Microbiologist
CDER/OPS/NDMS
cc: Rajesh Venugopal
Regulatory Health Project Manager
CDER/OND/OHOP/DOPI
SUBJECT: Product Quality Microbiology assessment of Microbial Limits for Olaparib [Submission Date: 03 February 2014]

The NDA for Olaparib does not include a microbial limits release specification for drug product release or stability; however, the applicant provides a suitable rationale for the exclusion of this testing. Therefore, this submission is recommended for approval from the standpoint of product quality microbiology.

The proposed drug product containing olaparib is a solid tablet with a hypromellose capsule shell.

The applicant presents a rationale for waiving Microbial Limits testing for product release and stability. The rationale states that controls on incoming materials, manufacturing areas, and packaging are in place to ensure microbiological quality. The applicant also provides stability data to demonstrate a lack of microbial growth in the finished product.

The drug product is produced by [redacted] All manufacturing steps take place at a temperature range of [redacted]

Microbial limits testing was performed for three primary stability batches. Specifications for these studies are in agreement with those described in USP <1111>, and include a total aerobic microbial count of NMT [redacted] CFU/g, a total yeast and mold count of NMT [redacted] CFU/g, and the

Reference ID: 3452968
absence of *Escherichia coli* per gram. Testing was performed using methods described in USP 61 and USP 62. Microbiological testing was performed at initial and final timepoints. For intermediate timepoints,  was monitored as a surrogate for microbiological testing with a specification of NMT (6). Within the three stability batches, testing was performed on product held at 25°C/60% RH (36 months), 30°C/65% RH (36 months) 30°C/75% RH (36 months), and 40°C/75% RH (6 months). All acceptance criteria for microbiological stability testing were met.

**ADEQUATE**

Reviewer Comments – The applicant’s proposal to waive microbial limits testing for product release and stability is acceptable.

**END**
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------------------------------
ERIKA A PFEILER
02/12/2014

JOHN W METCALFE
02/12/2014

I concur.